Corrona's subscribers have access to data, thought leaders, and clinical insight specific to their medical affairs, scientific, and commercial needs.
All Corrona registries are non-exclusive and open to new subscribers. Any data element on any questionnaire is available for analysis to any subscriber. The results of the query can be retained strictly with the subscriber, or submitted for an abstract or manuscript development. Subscribers are encouraged to propose new data elements to be added to the questionnaires, encouraging a more dynamic and flexible data tool to keep pace with an evolving marketplace.
Corrona provides a unique, real time and representative view of the 'state of the disease' management in the dynamic and evolving US marketplace. Customized data analytics can provide value for planning a launch, developing a campaign for a newly approved product, and leveraging experience with mature agents in this unique market space.
Corrona welcomes inquiries for the possible uses of our data. Contact us at: firstname.lastname@example.org.
Illustrative types of studies subscribers can initiate:
|Comparative effectiveness research (CER)||Drug CER; Head-to-Head CER comparisons.|
|Treatment patterns||Time from First Non-biologic DMARD to First Biologic or Small Molecule; Methotrexate Use by Line of Therapy; Patient profile by line of therapy; Sequence of Biologic or Small Molecule Switching with Clinical Disease Activity Data and Reasons for Switching.|
|Outcomes||Use of Mechanical Aids over Time; Time to 1st Biologic and Response; Time to Remission or Low Disease Activity by Line of Therapy.|
|Persistency||Individual Drug Adherence Patient Profiles; Persistency of Mono Therapy; Persistency of Combination Therapy.|
|Safety and adverse events||Evaluation of Association between Events of Interest and Classes of Drug (for example anti-TNFs); Post Approval Studies (or PASs) Reporting; Contextual Adverse Event Rates and Evaluation of Rates in Sub-Populations of Interest.|
|Subpopulation analysis||Biologic use by Demographics or Clinical Characteristics Categories; Comparison by Route of Administration of Agent (Longitudinal Analysis); Evaluation of Treatment Patterns, Clinical and Demographic Characteristics in Methotrexate Naïve Patients.|
|Patient reported outcomes||Evaluation of Morning Joint Stiffness; Longitudinal Analysis of Use of Pain Medications; Efficacy as Measured by Change in Patient Reported Pain/Global Assessment VAS/Fatigue.|